TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model

@article{Ohta2009TSU68AA,
  title={TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model},
  author={Manabu Ohta and Toshiki Kawabata and Masayoshi Yamamoto and Tatsuo Tanaka and Hirotoshi Kikuchi and Yoshihiro Hiramatsu and Kinji Kamiya and Megumi Baba and Hiroyuki Konno},
  journal={Surgery Today},
  year={2009},
  volume={39},
  pages={1046-1053}
}
PurposeCombination therapy using antiangiogenic and cytotoxic agents is a useful strategy for advanced cancer, but the mechanism has not yet been elucidated. Moreover, there is a persistent paradox that destroying tumor vasculature with antiangiogenic agents disturbs the delivery of cytotoxic agents. It has been hypothesized that antiangiogenic agents can lead to normalization of tumor vessels that are structurally and functionally abnormal. The normalization means enhancing the deliver of… 
TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar
TLDR
TSP-1 may be a potential biomarker for predicting the normalization window of colon cancer vessels and had no effect on the proliferation of SW620 cells, suggesting that the reduction in T SP-1 was associated with increased oxygen content during vascular normalization, rather than inhibited cell proliferation.
Recent concepts of antiangiogenic therapy
TLDR
The present understanding of the mechanisms of action of antiangiogenic agents is summarized, and the future prospects of antiANGiogenic therapies are discussed.
Antiangiogenic therapy: a novel approach to overcome tumor hypoxia.
TLDR
The use of antiangiogenic agents provides a new approach to overcome the hypoxia problem, and ultimately improves the efficacy of radiation therapy, in solid tumors.
Recombinant Human Endostatin Normalizes Tumor Vasculature and Enhances Radiation Response in Xenografted Human Nasopharyngeal Carcinoma Models
TLDR
Endostar normalized tumor vasculature, which alleviated hypoxia and significantly sensitized the function of radiation in anti-tumor in human NPC, which provides an important experimental basis for combining endostar with radiation therapy in human NPCs.
Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment
Malignant gliomas can be counted to the most devastating tumors in humans. Novel therapies do not achieve significant prolonged survival rates. The cancer cells have an impact on the surrounding
Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma
TLDR
The results of the present study suggest that the co-administration of Endostar and cisPlatin may aid in the optimization of the antitumor activity of cisplatin.
Normalization of the vasculature for treatment of cancer and other diseases.
TLDR
The pathophysiology of tumor angiogenesis, the molecular underpinnings and functional consequences of vascular normalization, and the implications for treatment of cancer and nonmalignant diseases are reviewed.
Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions.
TLDR
This review focuses on chemoresistance in GBM induced by stromal cells, including the endothelium of blood vessels, astrocytes, and myeloid cells, as well as non-cellular factors in the tumor microenvironment.
FGFR a promising druggable target in cancer: Molecular biology and new drugs.
TLDR
This review summarizes the current status of treatments targeting FGFR, focusing on the trials that are evaluating the FGFR profile as inclusion criteria: Multi-Target, Pan-FGFR Inhibitors and anti-FGF (Fibroblast Growth Factor)/FGFR Monoclonal Antibodies.
Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416.
TLDR
The results suggest that the structural and functional normalization of the tumor vasculature by the pretreatment with PE-SU5416 enabled liposomes to reach the deeper regions within tumor tissues, leading to more potent antitumor activity of PL-PTX.
...
1
2
3
...

References

SHOWING 1-10 OF 34 REFERENCES
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
TLDR
Oral or i.p. administration of SU6668 in athymic mice resulted in significant growth inhibition of a diverse panel of human tumor xenografts of glioma, melanoma, lung, colon, ovarian, and epidermoid origin, and intravital multifluorescence videomicroscopy of C6glioma xenografteds in the dorsal skinfold chamber model revealed thatSU6668 treatment suppressed tumor angiogenesis.
Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.
TLDR
VEGF receptor inhibitors increased endothelial cell apoptosis, suggesting that VEGF may serve as an endothelial survival factor.
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
TLDR
This study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor.
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
TLDR
Adding bevacizumab to chemotherapy failed to increase survival in patients with previously treated and refractory metastatic breast cancer, and addition of vatalanib, a kinase inhibitor developed as a VEGF receptor-selective agent, to chemotherapy did not show a similar benefit in metastatic colorectal cancer patients.
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
TLDR
Emerging evidence supporting an alternative hypothesis is reviewed—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery.
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
TLDR
Data suggest that SU6668 may prevent tumor endothelial cell survival directly (vascular endothelial growth factor) and indirectly (pericyte coverage) by affecting endothelium cell survival mechanisms.
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
TLDR
Using a mathematical model to simulate IFP and IFV profiles in tumors, it is shown that antiangiogenic therapy can decrease IFP by decreasing the tumor size, vascular hydraulic permeability, and/or the surface area per unit tissue volume of tumor vessels.
Effect of angiogenesis inhibitor TNP‐470 on the progression of human gastric cancer xenotransplanted into nude mice
TLDR
TNP‐470 was revealed to have strong inhibitory activity not only on primary tumors and liver metastases but also against peritoneal dissemination, suggesting that this agent may provide a new approach to the treatment of gastric cancer.
Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470.
TLDR
Results indicate that the angiogenesis inhibitor TNP-470 has a strong inhibitory activity against in vivo hepatic metastasis of human colon cancer.
Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors
TLDR
It is demonstrated that blocking vascular endothelial growth factor signaling by DC101 (a VEGF-receptor-2 antibody) decreases interstitial fluid pressure, not by restoring lymphatic function, but by producing a morphologically and functionally “normalized” vascular network.
...
1
2
3
4
...